Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saad Z Usmani

Showing results (21-30 of 253) with videos related to

Pageof 26
Sort By:
Journal of Nephrology|March 10, 2007
A rare case of postinfectious glomerulonephritis caused by pneumococcus in an adult patientSaad Z Usmani, Zainab Shahid, Donald Wheeler, et al.
Drug Design, Development and Therapy|March 31, 2017
Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myelomaReed Friend, Manisha Bhutani, Peter M Voorhees, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Induction Therapy for Newly Diagnosed Multiple MyelomaBarry Paul, Brea Lipe, Enrique M Ocio, et al.
The American Journal of the Medical Sciences|August 19, 2007
Myeloid sarcoma presenting with acute renal failure and bilateral ureteral obstruction: a case report and review of the literatureSaad Z Usmani, Zainab Shahid, Husain Saleh, et al.
Journal of Hematology & Oncology|October 28, 2010
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1Saad Z Usmani, Robert D Bona, Gabriela Chiosis, et al.
Bone Marrow Transplantation|August 10, 2020
Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challengesBinod Dhakal, Parameswaran N Hari, Saad Z Usmani, et al.
Frontiers in Immunology|October 9, 2018
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of ResistanceNiels W C J van de Donk, Saad Z Usmani
Future Oncology (London, England)|July 27, 2023
Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myelomaThomas G Martin, Deepu Madduri, Lida Pacaud, et al.
Experimental Hematology & Oncology|December 6, 2012
Thalidomide and its analogues in the treatment of Multiple MyelomaTahir Latif, Nabeel Chauhan, Rashid Khan, et al.
Seminars in Oncology|May 15, 2016
Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disordersManisha Bhutani, Zainab Shahid, Alicia Schnebelen, et al.
Pageof 26

Showing results (21-30 of 253) with videos related to

Sort By:
Pageof 26
Journal of Nephrology|March 10, 2007
A rare case of postinfectious glomerulonephritis caused by pneumococcus in an adult patientSaad Z Usmani, Zainab Shahid, Donald Wheeler, et al.
Drug Design, Development and Therapy|March 31, 2017
Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myelomaReed Friend, Manisha Bhutani, Peter M Voorhees, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Induction Therapy for Newly Diagnosed Multiple MyelomaBarry Paul, Brea Lipe, Enrique M Ocio, et al.
The American Journal of the Medical Sciences|August 19, 2007
Myeloid sarcoma presenting with acute renal failure and bilateral ureteral obstruction: a case report and review of the literatureSaad Z Usmani, Zainab Shahid, Husain Saleh, et al.
Journal of Hematology & Oncology|October 28, 2010
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1Saad Z Usmani, Robert D Bona, Gabriela Chiosis, et al.
Bone Marrow Transplantation|August 10, 2020
Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challengesBinod Dhakal, Parameswaran N Hari, Saad Z Usmani, et al.
Frontiers in Immunology|October 9, 2018
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of ResistanceNiels W C J van de Donk, Saad Z Usmani
Future Oncology (London, England)|July 27, 2023
Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myelomaThomas G Martin, Deepu Madduri, Lida Pacaud, et al.
Experimental Hematology & Oncology|December 6, 2012
Thalidomide and its analogues in the treatment of Multiple MyelomaTahir Latif, Nabeel Chauhan, Rashid Khan, et al.
Seminars in Oncology|May 15, 2016
Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disordersManisha Bhutani, Zainab Shahid, Alicia Schnebelen, et al.
Pageof 26